Ferrer Obtains the Distribution Rights for Treprostinil Inhalation Solution Including the Potential Indications for Idiopathic Pulmonary Fibrosis IPF and Progressive Pulmonary Fibrosis PPF

The international pharmaceutical BCorp company Ferrer continues to strengthen its focus on pulmonary vascular and interstitial lung diseases by announcing the expansion of its current distribution agreement with United Therapeutics Corporation for Tyvaso a pharmaceutical drugdevice combination product authorized for the treatment of WHO Group 3 Pulmonary Hypertension associated with Interstitial Lung Disease PHILD and for WHO Group 1 Pulmonary Arterial Hypertension PAH.

Related Keywords

Argentina ,Israel ,Canada ,Chile ,United Kingdom ,Colombia ,China ,Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Japan ,Dominican Republic ,Carlo Ferri ,European Union ,Business Development ,United Therapeutics Corporation Nasdaq ,United Therapeutics Corporation ,Interstitial Lung Disease ,Arterial Hypertension ,Idiopathic Pulmonary Fibrosis ,Progressive Pulmonary Fibrosis ,Chief Scientific ,Business Development Officer ,Media Contact ,